GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » PB Ratio

Concert Pharmaceuticals (Concert Pharmaceuticals) PB Ratio : 3.01 (As of May. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Concert Pharmaceuticals's share price is $8.37. Concert Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2022 was $2.78. Hence, Concert Pharmaceuticals's PB Ratio of today is 3.01.

The historical rank and industry rank for Concert Pharmaceuticals's PB Ratio or its related term are showing as below:

CNCE' s PB Ratio Range Over the Past 10 Years
Min: 0.84   Med: 2.23   Max: 5.31
Current: 3.01

During the past 11 years, Concert Pharmaceuticals's highest PB Ratio was 5.31. The lowest was 0.84. And the median was 2.23.

CNCE's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.5 vs CNCE: 3.01

During the past 12 months, Concert Pharmaceuticals's average Book Value Per Share Growth Rate was -9.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -23.30% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -9.60% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Concert Pharmaceuticals was 41.30% per year. The lowest was -23.30% per year. And the median was 3.50% per year.

Back to Basics: PB Ratio


Concert Pharmaceuticals PB Ratio Historical Data

The historical data trend for Concert Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals PB Ratio Chart

Concert Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 1.75 2.17 3.07 0.97

Concert Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.97 1.54 1.58 2.41

Competitive Comparison of Concert Pharmaceuticals's PB Ratio

For the Biotechnology subindustry, Concert Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concert Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's PB Ratio falls into.



Concert Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Concert Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2022)
=8.37/2.78
=3.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Concert Pharmaceuticals  (NAS:CNCE) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Concert Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Executives
James V Cassella officer: Chief Development Officer 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker officer: CFO, PFO 175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart officer: Chief Operating Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie officer: Chief Legal Officer CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung director, officer: Chief Executive Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt director
Thomas G Auchincloss director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich director 1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland director C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Concert Pharmaceuticals (Concert Pharmaceuticals) Headlines

From GuruFocus

This Insider Just Sold Shares of Concert Pharmaceuticals Inc

By GuruFocus Research GuruFocus Editor 01-10-2023

Concert Pharmaceuticals Announces Pricing of Public Offering

By Business Wire Business Wire 06-02-2022

Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022